IDEXX's equine topical anti-inflammatory gains FDA approval

Article

IDEXX Laboratories Inc. received approval from the U.S. Food and Drug Administration (FDA) to market and sell Surpass? (1% diclofenac sodium) Topical Anti-Inflammatory Cream, a new treatment for horses with pain and lameness due to osteo-arthritis.

IDEXX Laboratories Inc. received approval from the U.S. Food and Drug Administration (FDA) to market and sell Surpass™ (1% diclofenac sodium) Topical Anti-Inflammatory Cream, a new treatment for horses with pain and lameness due to osteo- arthritis. Surpass topical cream represents the first equine pharmaceutical use of a topical liposomal formulation of the FDA-approved nonsteroidal anti-inflammatory drug, diclofenac. The product is labeled as a veterinary-only prescription medication to be used under the supervision of a licensed, practicing veterinarian.

"Used in a comprehensive pain management program, Surpass topical cream offers localized pain relief without many of the side effects seen with systemic products," IDEXX President and CEO Jonathan Ayers says. "Surpass is manufactured to exacting standards for incorporation of the powerful pain reliever, diclofenac, in a proprietary liposomal formulation. This means practitioners can count on consistency in every tube."

For fastest response, call

(800) 759-0834

www.idexx.com

Related Videos
© 2024 MJH Life Sciences

All rights reserved.